GeoVax Labs, Inc. (NASDAQ:GOVX) Short Interest Up 33.5% in March

GeoVax Labs, Inc. (NASDAQ:GOVX) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 815,200 shares, a growth of 33.5% from the March 15th total of 610,600 shares. Based on an average daily volume of 587,800 shares, the days-to-cover ratio is currently 1.4 days. Approximately 9.2% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. D. Boral Capital restated a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a research report on Thursday, April 10th. Alliance Global Partners decreased their price target on shares of GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a research note on Tuesday, April 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of GeoVax Labs in a research note on Wednesday. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GeoVax Labs has a consensus rating of “Buy” and a consensus target price of $12.90.

GeoVax Labs Price Performance

GeoVax Labs stock traded down $0.07 during trading hours on Friday, reaching $0.83. The stock had a trading volume of 460,713 shares, compared to its average volume of 604,785. The company has a fifty day simple moving average of $1.36 and a 200-day simple moving average of $1.94. GeoVax Labs has a 52 week low of $0.73 and a 52 week high of $11.18. The stock has a market cap of $11.48 million, a PE ratio of -0.15 and a beta of 3.70.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.49. The business had revenue of $3.00 million during the quarter, compared to the consensus estimate of $2.38 million. Research analysts predict that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds have recently made changes to their positions in GOVX. Citadel Advisors LLC bought a new stake in GeoVax Labs in the fourth quarter valued at $104,000. Northern Trust Corp purchased a new stake in shares of GeoVax Labs in the 4th quarter worth about $29,000. Geode Capital Management LLC boosted its stake in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of GeoVax Labs during the 3rd quarter valued at about $97,000. 6.09% of the stock is owned by hedge funds and other institutional investors.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.